At 19.3% CAGR, Asia Pacific Biologics Market is Projected to be Worth US$ 4,17,082.9 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Asia Pacific biologics market was valued at US$ 1,01,590.5 million in 2023 and is expected to reach US$ 4,17,082.9 million by 2031, registering a CAGR of 19.3% from 2023 to 2031. Preference for outsourcing manufacturing operations and increasing prevalence of chronic disease are among the critical factors attributed to drive the Asia Pacific biologics market growth.

Biologics manufacturing is a complex process whose success depends on the proper execution and monitoring of all operations. The manufacturing facilities need trained personnel with technical knowledge of bioprocessing and process engineering. Managing the attempts to reach the first clinical trial using a manual and open manufacturing method and then building a more commercially suitable process can be tricky for an experienced team. Thus, manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization operations. CDMOs provide product development, clinical trial support, manufacturing, and commercialization services to biologics companies on a contract basis. Partnering with CDMO enables scalability and access to technical expertise without overhead costs, along with higher speed to market and greater cost efficiencies for biologics manufacturers. In April 2022, ThermoGenesis established its own CDMO facility in California, US, to provide CDMO services to cell and gene therapy manufacturers. Using its expertise, the company focuses on manufacturing chimeric antigen receptor-T cell (CAR-T cell), T-cell receptor (TCR), tumor-infiltrating leukocyte (TIL), natural killer cell (NK), iPSC, and mesenchymal stem cell (MSC). Outsourcing biologics manufacturing to CDMOs proves cost-effective for manufacturers. Additionally, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing biologics. Thus, the surging preference for outsourcing biologics manufacturing operations to CDMOs fuels the biologics market growth.

On the contrary, the high cost of biologics hampers the growth of Asia Pacific biologics market.

Based on product, the Asia Pacific biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held 36.7% market share in 2023, amassing US$ 37,288.73 million. It is projected to garner US$ 1,60,871.25 million by 2031 to register 20.1% CAGR during 2023-2031.

In terms of application, the Asia Pacific biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held 43.6% share of Asia Pacific biologics market in 2023, amassing US$ 44,297.21 million. It is anticipated to garner US$ 1,90,598.38 million by 2031 to expand at 19.9% CAGR during 2023-2031.

By source, the Asia Pacific biologics market is bifurcated into mammalian and microbial. The mammalian segment held 61.1% share of Asia Pacific biologics market in 2023, amassing US$ 62,059.15 million. It is projected to garner US$ 2,46,487.79 million by 2031 to expand at 18.7% CAGR from 2023 to 2031.

Based on manufacturing, the Asia Pacific biologics market is bifurcated into outsourced and in-house. The outsourced segment held 75.2% share of Asia Pacific biologics market in 2023, amassing US$ 76,363.80 million. It is predicted to garner US$ 3,20,387.57 million by 2031 to expand at 19.6% CAGR between 2023 and 2031.

Based on country, the Asia Pacific biologics market is categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 30.5% share of Asia Pacific biologics market in 2023. It was assessed at US$ 30,985.09 million in 2023 and is likely to hit US$ 1,31,214.29 million by 2031, registering a CAGR of 19.8% during 2023-2031.

Key players operating in the Asia Pacific biologics market are AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a., among others.

• In Jan 2024, AGC Biologics plans to construct a new manufacturing facility at AGC Inc.'s Yokohama Technical Center in Japan. The new site is a part of our strategic growth strategy to create more high-quality pharmaceutical development and manufacturing services in the Asia region that can help meet the global demand for biologics and advanced therapy medicinal products (ATMPs). The facility is expected to be operational in 2026.
• In Nov 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com